img

Global Inactivated Influenza Virus Vaccine Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Inactivated Influenza Virus Vaccine Market Insights, Forecast to 2034

The global Inactivated Influenza Virus Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key manufacturers of Inactivated Influenza Virus Vaccine include CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer, Johnson & Johnson, Jiangsu Jindik Biotechnology Co., Ltd and Beijing Kexing Biological Products Co., Ltd, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Inactivated Influenza Virus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Inactivated Influenza Virus Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Inactivated Influenza Virus Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Inactivated Influenza Virus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2024. Identification of the major stakeholders in the global Inactivated Influenza Virus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2034. Evaluation and forecast the market size for Inactivated Influenza Virus Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer, Johnson & Johnson, Jiangsu Jindik Biotechnology Co., Ltd and Beijing Kexing Biological Products Co., Ltd, etc.



By Company


CSL
GSK
Sanofi Pasteur
Mylan
AstraZeneca
Pfizer
Johnson & Johnson
Jiangsu Jindik Biotechnology Co., Ltd
Beijing Kexing Biological Products Co., Ltd
Jiangsu Kangrun Biotechnology Co., Ltd
Hualan Bio Vaccines Co., Ltd
Dalian Yalifeng Biopharmaceutical Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Changchun Institute of Biological Products Co., Ltd
Lanzhou Institute of Biological Products Co., Ltd
Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
Emmi Chengxin Biopharmaceutical Co., Ltd
Segment by Type
Whole Virus Vaccine
Subunit Vaccine

Segment by Application


Hospital
Clinic

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Inactivated Influenza Virus Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inactivated Influenza Virus Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Inactivated Influenza Virus Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Whole Virus Vaccine
1.2.3 Subunit Vaccine
1.3 Market by Application
1.3.1 Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Inactivated Influenza Virus Vaccine Sales Estimates and Forecasts 2018-2034
2.2 Global Inactivated Influenza Virus Vaccine Revenue by Region
2.2.1 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global Inactivated Influenza Virus Vaccine Revenue by Region (2018-2024)
2.2.3 Global Inactivated Influenza Virus Vaccine Revenue by Region (2024-2034)
2.2.4 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2018-2034)
2.3 Global Inactivated Influenza Virus Vaccine Sales Estimates and Forecasts 2018-2034
2.4 Global Inactivated Influenza Virus Vaccine Sales by Region
2.4.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global Inactivated Influenza Virus Vaccine Sales by Region (2018-2024)
2.4.3 Global Inactivated Influenza Virus Vaccine Sales by Region (2024-2034)
2.4.4 Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Inactivated Influenza Virus Vaccine Sales by Manufacturers
3.1.1 Global Inactivated Influenza Virus Vaccine Sales by Manufacturers (2018-2024)
3.1.2 Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Inactivated Influenza Virus Vaccine in 2022
3.2 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers
3.2.1 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Inactivated Influenza Virus Vaccine Revenue in 2022
3.3 Global Key Players of Inactivated Influenza Virus Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Inactivated Influenza Virus Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Inactivated Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Inactivated Influenza Virus Vaccine Sales by Type
4.1.1 Global Inactivated Influenza Virus Vaccine Historical Sales by Type (2018-2024)
4.1.2 Global Inactivated Influenza Virus Vaccine Forecasted Sales by Type (2024-2034)
4.1.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2018-2034)
4.2 Global Inactivated Influenza Virus Vaccine Revenue by Type
4.2.1 Global Inactivated Influenza Virus Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Inactivated Influenza Virus Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Inactivated Influenza Virus Vaccine Price by Type
4.3.1 Global Inactivated Influenza Virus Vaccine Price by Type (2018-2024)
4.3.2 Global Inactivated Influenza Virus Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Inactivated Influenza Virus Vaccine Sales by Application
5.1.1 Global Inactivated Influenza Virus Vaccine Historical Sales by Application (2018-2024)
5.1.2 Global Inactivated Influenza Virus Vaccine Forecasted Sales by Application (2024-2034)
5.1.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2018-2034)
5.2 Global Inactivated Influenza Virus Vaccine Revenue by Application
5.2.1 Global Inactivated Influenza Virus Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Inactivated Influenza Virus Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Inactivated Influenza Virus Vaccine Price by Application
5.3.1 Global Inactivated Influenza Virus Vaccine Price by Application (2018-2024)
5.3.2 Global Inactivated Influenza Virus Vaccine Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Inactivated Influenza Virus Vaccine Market Size by Type
6.1.1 US & Canada Inactivated Influenza Virus Vaccine Sales by Type (2018-2034)
6.1.2 US & Canada Inactivated Influenza Virus Vaccine Revenue by Type (2018-2034)
6.2 US & Canada Inactivated Influenza Virus Vaccine Market Size by Application
6.2.1 US & Canada Inactivated Influenza Virus Vaccine Sales by Application (2018-2034)
6.2.2 US & Canada Inactivated Influenza Virus Vaccine Revenue by Application (2018-2034)
6.3 US & Canada Inactivated Influenza Virus Vaccine Market Size by Country
6.3.1 US & Canada Inactivated Influenza Virus Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada Inactivated Influenza Virus Vaccine Sales by Country (2018-2034)
6.3.3 US & Canada Inactivated Influenza Virus Vaccine Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Inactivated Influenza Virus Vaccine Market Size by Type
7.1.1 Europe Inactivated Influenza Virus Vaccine Sales by Type (2018-2034)
7.1.2 Europe Inactivated Influenza Virus Vaccine Revenue by Type (2018-2034)
7.2 Europe Inactivated Influenza Virus Vaccine Market Size by Application
7.2.1 Europe Inactivated Influenza Virus Vaccine Sales by Application (2018-2034)
7.2.2 Europe Inactivated Influenza Virus Vaccine Revenue by Application (2018-2034)
7.3 Europe Inactivated Influenza Virus Vaccine Market Size by Country
7.3.1 Europe Inactivated Influenza Virus Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe Inactivated Influenza Virus Vaccine Sales by Country (2018-2034)
7.3.3 Europe Inactivated Influenza Virus Vaccine Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Inactivated Influenza Virus Vaccine Market Size
8.1.1 China Inactivated Influenza Virus Vaccine Sales (2018-2034)
8.1.2 China Inactivated Influenza Virus Vaccine Revenue (2018-2034)
8.2 China Inactivated Influenza Virus Vaccine Market Size by Application
8.2.1 China Inactivated Influenza Virus Vaccine Sales by Application (2018-2034)
8.2.2 China Inactivated Influenza Virus Vaccine Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Inactivated Influenza Virus Vaccine Market Size by Type
9.1.1 Asia Inactivated Influenza Virus Vaccine Sales by Type (2018-2034)
9.1.2 Asia Inactivated Influenza Virus Vaccine Revenue by Type (2018-2034)
9.2 Asia Inactivated Influenza Virus Vaccine Market Size by Application
9.2.1 Asia Inactivated Influenza Virus Vaccine Sales by Application (2018-2034)
9.2.2 Asia Inactivated Influenza Virus Vaccine Revenue by Application (2018-2034)
9.3 Asia Inactivated Influenza Virus Vaccine Sales by Region
9.3.1 Asia Inactivated Influenza Virus Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia Inactivated Influenza Virus Vaccine Revenue by Region (2018-2034)
9.3.3 Asia Inactivated Influenza Virus Vaccine Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 CSL
11.1.1 CSL Company Information
11.1.2 CSL Overview
11.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 CSL Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 CSL Recent Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Overview
11.2.3 GSK Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 GSK Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Company Information
11.3.2 Sanofi Pasteur Overview
11.3.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Pasteur Recent Developments
11.4 Mylan
11.4.1 Mylan Company Information
11.4.2 Mylan Overview
11.4.3 Mylan Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Mylan Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Mylan Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Overview
11.5.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 AstraZeneca Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Pfizer Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Information
11.7.2 Johnson & Johnson Overview
11.7.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Johnson & Johnson Recent Developments
11.8 Jiangsu Jindik Biotechnology Co., Ltd
11.8.1 Jiangsu Jindik Biotechnology Co., Ltd Company Information
11.8.2 Jiangsu Jindik Biotechnology Co., Ltd Overview
11.8.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
11.9 Beijing Kexing Biological Products Co., Ltd
11.9.1 Beijing Kexing Biological Products Co., Ltd Company Information
11.9.2 Beijing Kexing Biological Products Co., Ltd Overview
11.9.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
11.10 Jiangsu Kangrun Biotechnology Co., Ltd
11.10.1 Jiangsu Kangrun Biotechnology Co., Ltd Company Information
11.10.2 Jiangsu Kangrun Biotechnology Co., Ltd Overview
11.10.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
11.11 Hualan Bio Vaccines Co., Ltd
11.11.1 Hualan Bio Vaccines Co., Ltd Company Information
11.11.2 Hualan Bio Vaccines Co., Ltd Overview
11.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
11.12 Dalian Yalifeng Biopharmaceutical Co., Ltd
11.12.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information
11.12.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Overview
11.12.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
11.13 Shanghai Institute of Biological Products Co., Ltd
11.13.1 Shanghai Institute of Biological Products Co., Ltd Company Information
11.13.2 Shanghai Institute of Biological Products Co., Ltd Overview
11.13.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
11.14 Changchun Institute of Biological Products Co., Ltd
11.14.1 Changchun Institute of Biological Products Co., Ltd Company Information
11.14.2 Changchun Institute of Biological Products Co., Ltd Overview
11.14.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
11.15 Lanzhou Institute of Biological Products Co., Ltd
11.15.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
11.15.2 Lanzhou Institute of Biological Products Co., Ltd Overview
11.15.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.15.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
11.16 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
11.16.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information
11.16.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Overview
11.16.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.16.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
11.17 Emmi Chengxin Biopharmaceutical Co., Ltd
11.17.1 Emmi Chengxin Biopharmaceutical Co., Ltd Company Information
11.17.2 Emmi Chengxin Biopharmaceutical Co., Ltd Overview
11.17.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.17.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Inactivated Influenza Virus Vaccine Industry Chain Analysis
12.2 Inactivated Influenza Virus Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Inactivated Influenza Virus Vaccine Production Mode & Process
12.4 Inactivated Influenza Virus Vaccine Sales and Marketing
12.4.1 Inactivated Influenza Virus Vaccine Sales Channels
12.4.2 Inactivated Influenza Virus Vaccine Distributors
12.5 Inactivated Influenza Virus Vaccine Customers
13 Market Dynamics
13.1 Inactivated Influenza Virus Vaccine Industry Trends
13.2 Inactivated Influenza Virus Vaccine Market Drivers
13.3 Inactivated Influenza Virus Vaccine Market Challenges
13.4 Inactivated Influenza Virus Vaccine Market Restraints
14 Key Findings in The Global Inactivated Influenza Virus Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Whole Virus Vaccine
Table 3. Major Manufacturers of Subunit Vaccine
Table 4. Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Inactivated Influenza Virus Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Inactivated Influenza Virus Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Inactivated Influenza Virus Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 8. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2024-2034)
Table 10. Global Inactivated Influenza Virus Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 11. Global Inactivated Influenza Virus Vaccine Sales by Region (2018-2024) & (K Units)
Table 12. Global Inactivated Influenza Virus Vaccine Sales by Region (2024-2034) & (K Units)
Table 13. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2024-2034)
Table 15. Global Inactivated Influenza Virus Vaccine Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Inactivated Influenza Virus Vaccine Sales Share by Manufacturers (2018-2024)
Table 17. Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Inactivated Influenza Virus Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Inactivated Influenza Virus Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Inactivated Influenza Virus Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Inactivated Influenza Virus Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Inactivated Influenza Virus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Influenza Virus Vaccine as of 2022)
Table 23. Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Inactivated Influenza Virus Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Inactivated Influenza Virus Vaccine Sales by Type (2018-2024) & (K Units)
Table 28. Global Inactivated Influenza Virus Vaccine Sales by Type (2024-2034) & (K Units)
Table 29. Global Inactivated Influenza Virus Vaccine Sales Share by Type (2018-2024)
Table 30. Global Inactivated Influenza Virus Vaccine Sales Share by Type (2024-2034)
Table 31. Global Inactivated Influenza Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Inactivated Influenza Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Inactivated Influenza Virus Vaccine Revenue Share by Type (2018-2024)
Table 34. Global Inactivated Influenza Virus Vaccine Revenue Share by Type (2024-2034)
Table 35. Inactivated Influenza Virus Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Inactivated Influenza Virus Vaccine Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Inactivated Influenza Virus Vaccine Sales by Application (2018-2024) & (K Units)
Table 38. Global Inactivated Influenza Virus Vaccine Sales by Application (2024-2034) & (K Units)
Table 39. Global Inactivated Influenza Virus Vaccine Sales Share by Application (2018-2024)
Table 40. Global Inactivated Influenza Virus Vaccine Sales Share by Application (2024-2034)
Table 41. Global Inactivated Influenza Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Inactivated Influenza Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Inactivated Influenza Virus Vaccine Revenue Share by Application (2018-2024)
Table 44. Global Inactivated Influenza Virus Vaccine Revenue Share by Application (2024-2034)
Table 45. Inactivated Influenza Virus Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Inactivated Influenza Virus Vaccine Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. US & Canada Inactivated Influenza Virus Vaccine Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Inactivated Influenza Virus Vaccine Sales by Type (2024-2034) & (K Units)
Table 49. US & Canada Inactivated Influenza Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Inactivated Influenza Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 51. US & Canada Inactivated Influenza Virus Vaccine Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Inactivated Influenza Virus Vaccine Sales by Application (2024-2034) & (K Units)
Table 53. US & Canada Inactivated Influenza Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Inactivated Influenza Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 55. US & Canada Inactivated Influenza Virus Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 56. US & Canada Inactivated Influenza Virus Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 58. US & Canada Inactivated Influenza Virus Vaccine Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Inactivated Influenza Virus Vaccine Sales by Country (2024-2034) & (K Units)
Table 60. Europe Inactivated Influenza Virus Vaccine Sales by Type (2018-2024) & (K Units)
Table 61. Europe Inactivated Influenza Virus Vaccine Sales by Type (2024-2034) & (K Units)
Table 62. Europe Inactivated Influenza Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Inactivated Influenza Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 64. Europe Inactivated Influenza Virus Vaccine Sales by Application (2018-2024) & (K Units)
Table 65. Europe Inactivated Influenza Virus Vaccine Sales by Application (2024-2034) & (K Units)
Table 66. Europe Inactivated Influenza Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Inactivated Influenza Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 68. Europe Inactivated Influenza Virus Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 69. Europe Inactivated Influenza Virus Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 71. Europe Inactivated Influenza Virus Vaccine Sales by Country (2018-2024) & (K Units)
Table 72. Europe Inactivated Influenza Virus Vaccine Sales by Country (2024-2034) & (K Units)
Table 73. China Inactivated Influenza Virus Vaccine Sales by Type (2018-2024) & (K Units)
Table 74. China Inactivated Influenza Virus Vaccine Sales by Type (2024-2034) & (K Units)
Table 75. China Inactivated Influenza Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Inactivated Influenza Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 77. China Inactivated Influenza Virus Vaccine Sales by Application (2018-2024) & (K Units)
Table 78. China Inactivated Influenza Virus Vaccine Sales by Application (2024-2034) & (K Units)
Table 79. China Inactivated Influenza Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Inactivated Influenza Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 81. Asia Inactivated Influenza Virus Vaccine Sales by Type (2018-2024) & (K Units)
Table 82. Asia Inactivated Influenza Virus Vaccine Sales by Type (2024-2034) & (K Units)
Table 83. Asia Inactivated Influenza Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Inactivated Influenza Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 85. Asia Inactivated Influenza Virus Vaccine Sales by Application (2018-2024) & (K Units)
Table 86. Asia Inactivated Influenza Virus Vaccine Sales by Application (2024-2034) & (K Units)
Table 87. Asia Inactivated Influenza Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Inactivated Influenza Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 89. Asia Inactivated Influenza Virus Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 90. Asia Inactivated Influenza Virus Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Inactivated Influenza Virus Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 92. Asia Inactivated Influenza Virus Vaccine Sales by Region (2018-2024) & (K Units)
Table 93. Asia Inactivated Influenza Virus Vaccine Sales by Region (2024-2034) & (K Units)
Table 94. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Type (2024-2034) & (K Units)
Table 96. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 98. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Application (2024-2034) & (K Units)
Table 100. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 102. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 103. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 105. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales by Country (2024-2034) & (K Units)
Table 107. CSL Company Information
Table 108. CSL Description and Major Businesses
Table 109. CSL Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. CSL Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. CSL Recent Developments
Table 112. GSK Company Information
Table 113. GSK Description and Major Businesses
Table 114. GSK Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. GSK Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. GSK Recent Developments
Table 117. Sanofi Pasteur Company Information
Table 118. Sanofi Pasteur Description and Major Businesses
Table 119. Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Sanofi Pasteur Recent Developments
Table 122. Mylan Company Information
Table 123. Mylan Description and Major Businesses
Table 124. Mylan Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Mylan Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Mylan Recent Developments
Table 127. AstraZeneca Company Information
Table 128. AstraZeneca Description and Major Businesses
Table 129. AstraZeneca Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. AstraZeneca Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. AstraZeneca Recent Developments
Table 132. Pfizer Company Information
Table 133. Pfizer Description and Major Businesses
Table 134. Pfizer Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Pfizer Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Pfizer Recent Developments
Table 137. Johnson & Johnson Company Information
Table 138. Johnson & Johnson Description and Major Businesses
Table 139. Johnson & Johnson Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Johnson & Johnson Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Johnson & Johnson Recent Developments
Table 142. Jiangsu Jindik Biotechnology Co., Ltd Company Information
Table 143. Jiangsu Jindik Biotechnology Co., Ltd Description and Major Businesses
Table 144. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
Table 147. Beijing Kexing Biological Products Co., Ltd Company Information
Table 148. Beijing Kexing Biological Products Co., Ltd Description and Major Businesses
Table 149. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Beijing Kexing Biological Products Co., Ltd Recent Developments
Table 152. Jiangsu Kangrun Biotechnology Co., Ltd Company Information
Table 153. Jiangsu Kangrun Biotechnology Co., Ltd Description and Major Businesses
Table 154. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
Table 157. Hualan Bio Vaccines Co., Ltd Company Information
Table 158. Hualan Bio Vaccines Co., Ltd Description and Major Businesses
Table 159. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Hualan Bio Vaccines Co., Ltd Recent Developments
Table 162. Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information
Table 163. Dalian Yalifeng Biopharmaceutical Co., Ltd Description and Major Businesses
Table 164. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
Table 167. Shanghai Institute of Biological Products Co., Ltd Company Information
Table 168. Shanghai Institute of Biological Products Co., Ltd Description and Major Businesses
Table 169. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Shanghai Institute of Biological Products Co., Ltd Recent Developments
Table 172. Changchun Institute of Biological Products Co., Ltd Company Information
Table 173. Changchun Institute of Biological Products Co., Ltd Description and Major Businesses
Table 174. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 175. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Changchun Institute of Biological Products Co., Ltd Recent Developments
Table 177. Lanzhou Institute of Biological Products Co., Ltd Company Information
Table 178. Lanzhou Institute of Biological Products Co., Ltd Description and Major Businesses
Table 179. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 180. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Lanzhou Institute of Biological Products Co., Ltd Recent Developments
Table 182. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information
Table 183. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Description and Major Businesses
Table 184. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 185. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
Table 187. Emmi Chengxin Biopharmaceutical Co., Ltd Company Information
Table 188. Emmi Chengxin Biopharmaceutical Co., Ltd Description and Major Businesses
Table 189. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 190. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 191. Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Inactivated Influenza Virus Vaccine Distributors List
Table 195. Inactivated Influenza Virus Vaccine Customers List
Table 196. Inactivated Influenza Virus Vaccine Market Trends
Table 197. Inactivated Influenza Virus Vaccine Market Drivers
Table 198. Inactivated Influenza Virus Vaccine Market Challenges
Table 199. Inactivated Influenza Virus Vaccine Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. Inactivated Influenza Virus Vaccine Product Picture
Figure 2. Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Inactivated Influenza Virus Vaccine Market Share by Type in 2022 & 2034
Figure 4. Whole Virus Vaccine Product Picture
Figure 5. Subunit Vaccine Product Picture
Figure 6. Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Inactivated Influenza Virus Vaccine Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Inactivated Influenza Virus Vaccine Report Years Considered
Figure 11. Global Inactivated Influenza Virus Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 12. Global Inactivated Influenza Virus Vaccine Revenue 2018-2034 (US$ Million)
Figure 13. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 14. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2018-2034)
Figure 15. Global Inactivated Influenza Virus Vaccine Sales 2018-2034 ((K Units)
Figure 16. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2018-2034)
Figure 17. US & Canada Inactivated Influenza Virus Vaccine Sales YoY (2018-2034) & (K Units)
Figure 18. US & Canada Inactivated Influenza Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 19. Europe Inactivated Influenza Virus Vaccine Sales YoY (2018-2034) & (K Units)
Figure 20. Europe Inactivated Influenza Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 21. China Inactivated Influenza Virus Vaccine Sales YoY (2018-2034) & (K Units)
Figure 22. China Inactivated Influenza Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Asia (excluding China) Inactivated Influenza Virus Vaccine Sales YoY (2018-2034) & (K Units)
Figure 24. Asia (excluding China) Inactivated Influenza Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales YoY (2018-2034) & (K Units)
Figure 26. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 27. The Inactivated Influenza Virus Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of Inactivated Influenza Virus Vaccine in the World: Market Share by Inactivated Influenza Virus Vaccine Revenue in 2022
Figure 29. Global Inactivated Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2018-2034)
Figure 31. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2018-2034)
Figure 32. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2018-2034)
Figure 33. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2018-2034)
Figure 34. US & Canada Inactivated Influenza Virus Vaccine Sales Market Share by Type (2018-2034)
Figure 35. US & Canada Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2018-2034)
Figure 36. US & Canada Inactivated Influenza Virus Vaccine Sales Market Share by Application (2018-2034)
Figure 37. US & Canada Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2018-2034)
Figure 38. US & Canada Inactivated Influenza Virus Vaccine Revenue Share by Country (2018-2034)
Figure 39. US & Canada Inactivated Influenza Virus Vaccine Sales Share by Country (2018-2034)
Figure 40. U.S. Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 41. Canada Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 42. Europe Inactivated Influenza Virus Vaccine Sales Market Share by Type (2018-2034)
Figure 43. Europe Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2018-2034)
Figure 44. Europe Inactivated Influenza Virus Vaccine Sales Market Share by Application (2018-2034)
Figure 45. Europe Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2018-2034)
Figure 46. Europe Inactivated Influenza Virus Vaccine Revenue Share by Country (2018-2034)
Figure 47. Europe Inactivated Influenza Virus Vaccine Sales Share by Country (2018-2034)
Figure 48. Germany Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 49. France Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 50. U.K. Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 51. Italy Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 52. Russia Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 53. China Inactivated Influenza Virus Vaccine Sales Market Share by Type (2018-2034)
Figure 54. China Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2018-2034)
Figure 55. China Inactivated Influenza Virus Vaccine Sales Market Share by Application (2018-2034)
Figure 56. China Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2018-2034)
Figure 57. Asia Inactivated Influenza Virus Vaccine Sales Market Share by Type (2018-2034)
Figure 58. Asia Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2018-2034)
Figure 59. Asia Inactivated Influenza Virus Vaccine Sales Market Share by Application (2018-2034)
Figure 60. Asia Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2018-2034)
Figure 61. Asia Inactivated Influenza Virus Vaccine Revenue Share by Region (2018-2034)
Figure 62. Asia Inactivated Influenza Virus Vaccine Sales Share by Region (2018-2034)
Figure 63. Japan Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 64. South Korea Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 65. China Taiwan Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 66. Southeast Asia Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 67. India Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 68. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales Market Share by Type (2018-2034)
Figure 69. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2018-2034)
Figure 70. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales Market Share by Application (2018-2034)
Figure 71. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2018-2034)
Figure 72. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Revenue Share by Country (2018-2034)
Figure 73. Middle East, Africa and Latin America Inactivated Influenza Virus Vaccine Sales Share by Country (2018-2034)
Figure 74. Brazil Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. Mexico Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. Turkey Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. Israel Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 78. GCC Countries Inactivated Influenza Virus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 79. Inactivated Influenza Virus Vaccine Value Chain
Figure 80. Inactivated Influenza Virus Vaccine Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries